Clinical Trial Search

Primary: Percentage Change From Baseline in Body Weight (%) After 13 Weeks of Treatment — -0.15; -1.57; -2.94 % Change from Baseline — p=0.0756

Primary: Acute Mountain Sickness (AMS-C) as Assessed by the Environmental Symptoms Questionnaire. — 0.36; 0.21 scores on a scale

Primary: To Demonstrate Non-inferior ROC Performance as Measured by the Area Under the Curve When Comparing 3-Ds Plus 3-D Images to the 2-D Images. — 0.907; 0.867 Proportion…

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE) — 8; 8; 11; 13 Participants

Primary: Number of Participants With Solicited Administration Site Events in Study Phase I (Safety Lead-in) — 0; 0; 0; 0 Participants

Primary: Percent of Time in Range 70-180 mg/dL — 43.9; 41.3; 61.2; 43.8 Percentage of time

Primary: Time-based Score — 553; 127; 143 score on a scale

Primary: Percentage of Participants With at Least One Serious Treatment-Emergent Adverse Event (TEAE) — 20 percentage of participants

Primary: Proportion of Eyes With Grade 3 or Higher Slit Lamp Findings — 0; 0 Proportion of Eyes

Primary: Percentage of Participants With Solicited Injection-site Adverse Events (AEs) From Day 1 Through Day 5 Post-vaccination — 9.1; 25.4; 51.8; 78.5 Percentage of participants

Primary: Proportion of Subjects With All Caries Arrested — 108; 101 Participants

Primary: Posttraumatic Stress Disorder Symptom Scale- Interview Version (PSS-I) — 11.4; 22.1 score on a scale

Primary: Patient-level CDR and Region-level PPV of rhPSMA7.3 (18F) PET for BCR of Prostate Cancer Using Histopathology or Imaging as a SoT — 54.1; 51.4; 51.6; 46.2 percentage

Primary: Number of Participants With Arrested Dental Caries, Assessed Using a Clinical Oral Examination — 48; 53 Participants

Primary: Specificity — 92.9; 93.8; 96.9 percentage